Endometriosis – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of endometriosis comprises epidemiological estimates of key patient populations in 14 pharmaceutical markets. We report both the diagnosed incidence and diagnosed prevalence of endometriosis for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s endometriosis forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of endometriosis over the forecast period?
- In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of endometriosis?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts nine endometriosis patient populations, as follows:
- Diagnosed incident cases.
- Diagnosed prevalent cases.
- Diagnosed surgically confirmed prevalent cases.
- Diagnosed clinically confirmed prevalent cases.
- Diagnosed suspected prevalent cases.
- Diagnosed stage I prevalent cases.
- Diagnosed stage II prevalent cases.
- Diagnosed stage III prevalent cases.
- Diagnosed stage IV prevalent cases.
Note: Coverage may vary by country.
